See what’s new.
Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag™ AAV Reagent
Isolere Bio by Donaldson, a Duke spinout, announces the launch of its manufacturing-grade IsoTag™ AAV reagent, marking a major milestone in advancing gene therapy manufacturing technologies.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.
Durham agtech startup Avalo secures $11M in funding
Avalo is a Duke agtech start-up based on technology developed by former postdoc Mariano Alvarez (Biology, Trinity) and Professor Cynthia Rudin (CS, Trinity).
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Lumotive Raises $45 Million to Expand Sales of Programmable Optical Semiconductors
Lumotive is a metamaterials start-up spun out of the labs of Professor David Smith and Associate Professor Maiken Mikkelsen (ECE, Pratt). Mikkelsen's former postdoc Gleb Akselrod is the founder and CTO.
Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies
DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).